新疆维吾尔妇女宫颈癌组织HPV16基因分子检测的研究
|
摘要
目的:人乳头瘤病毒16型(human papillomavirus,HPV16)是诱发妇女宫颈癌的启动因子,并与人类多种恶性肿瘤的发生密切相关。它的早期基因E6、E7是致癌的关键基因,在宫颈细胞中持续表达并为其癌化表型的维持所必需。新疆是我国宫颈癌高发区,新疆南部维吾尔妇女宮颈癌与HPV16感染密切相关,为进行新疆妇女宫颈癌病因研究及宫颈癌的预防及早期诊断,本文对新疆维吾尔妇女宫颈癌组织进行了HPV16 E6及E7基因的分子检测研究。为进一步了解新疆妇女宫颈癌组织中HPV16E6基因的结构特点,本研究对来自新疆的宫颈癌患者手术或活检标本中的HPV16E6基因进行了克隆及一级结构分析;对新疆地区宫颈不同病变组织进行了HPV16E6、E7基因检测;荧光定量聚合酶链反应(FQ-PCR)分析,探索新疆妇女宫颈不同病变组织中HPV16E6、E7基因的相对含量与病情变化的关系,为宫颈癌的筛查、早期诊断、预防及愈后评估提供新的分子生物学的方法。HPV16E6、E7蛋白是肿瘤特异性排斥抗原,是设计HPV疫苗公认的靶抗原。本研究开展新疆维吾尔妇女宫颈癌组织中HPV16E6、E7基因的克隆,融合蛋白的原核表达及准备抗血清的制备,为HPV16相关疾病的血清学诊断及HPV16E6、E7的疫苗研究提供物质基础。近年来,有关纳米材料的合成和应用方面的研究工作进展迅速,特别是纳米金,在分子领域的应用已成为研究的热点。研究采用固定于硅烷化片基上的捕获探针,特异性结合单链人乳头瘤病毒16型新疆株E6基
新猎医科大学博士学位论文
因(HPV 1 6E6)扩增片断,再与互补的纳米金颗粒标记的探针结合,
通过银染加强显色,初步建立了金标银染法快速检测HPv 1 6E6 DNA
的技术。从而为新疆妇女宫颈癌病因研究及宫颈癌的预防、诊断及治
疗的研究提供科学的理论依据。
方法:从浸泡在福尔马林的宫颈癌组织(10例)及福尔马林浸泡后
石蜡包埋的宫颈癌(59例)、宫颈上皮内瘤变(eervical intraepithelial
neoplasia,CIN65例)及宫颈炎(33例)组织中提取DNA;另外对一批
妇科门诊患者(96例)随机取宫颈管的脱落细胞及分泌物,作为对照,
用聚合酶链式反应(PCR)检测各组宫颈组织中人乳头瘤病毒16型
E6基因(HPV 1 6E6)。从19份新疆维吾尔族妇女宫颈癌活检组织标本
中提取组织DNA,作为模板,PCR扩增HPV 1 6E6全长基因,PCR产
物直接测序或克隆后测序,分析新疆维吾尔族妇女宫颈癌组织
HPV16E6基因的突变。以新疆妇女宫颈不同病变组织为源材料,以人
乳头瘤病毒16型(新疆株)E6基因(HpV 1 6E6,AF327851)及HPvl6E7
基因作为扩增的靶基因,同时以人p一actin基因片段作为内参照,借
助于设计的目的基因引物,两个特异的荧光探针,在筛选的FQ一PCR
优化反应体系中,同时对两个基因片段进行扩增,得到HPV 1 6E6及
HPV 1 6E7基因的相对含量。使用本实验室从新疆维吾尔族妇女宫颈癌
组织中克隆的人乳头瘤病毒16型的E7基因(HPV16E7),以pGEX一ZT
载体和大肠杆菌BL21(DE3)原核蛋白表达系统表达HPV16E7融合蛋
白(GST,HPV16E7),经亲和纯化定量后得到大量的GsT一HPv16E7融
和蛋白。根据HPV 16(新疆株)E6基因编码序列设计引物,从含有
HPV 1 6E6基因的质粒中扩增出含HPV 1 6E6基因的DNA片段,将所
得片段与pMD 18一T载体连接,转化到JM109大肠杆菌中,筛选的阳
性克隆扩增后,提取质粒DNA,酶切,回收目的片段,定向克隆到
PET28a中,转化JM109受体菌,从JM109受体菌中提出质粒,再转
化到BLZI(DE3)中,筛选出转化体,用IPTG诱导表达,在PAGE上
见到所表达的18kD的特异性的HPv16(新疆株)E6蛋白条带。从而为
人乳头瘤病毒16型的诊断、检测、疫苗研制等方面的研究提供了物质
基础。研究采用固定于硅烷化片基上的捕获探针,特异性结合单链人
一2一
中文摘要
乳头瘤病毒16型新疆株E6基因(HPV 1 6E6)扩增片断,再与互补的
纳米金颗粒标记的探针结合,通过银染加强显色,初步建立了金标银
染法快速检测HPV16E6 DNA的技术,同时辅以Real一time定量PCR、
地高辛斑点杂交进行平行比较和评价,确认了金标银染法检测的有效
性。
结果:PCR结果宫颈癌蜡块组织59例中HPv16E6阳性37例(阳
性率62.7%);宫颈上皮内瘤变(cIN)组织65例中HPv16E6阳性37
例(阳性率56.92%);石蜡包埋宫颈炎组织共33例,HPV16E6阳性
22例(阳性率“.67%);而宫颈管脱落细胞及分泌物共%例,HPV16E6
阳性3例(阳性率3.13%)。荧光定量PCR结果宫颈癌蜡块组织59例
p一actin均阳性,证实DNA提取方法可靠。从19份新疆维吾尔族妇
女宫颈癌活检组织标本中提取组织DNA,作为模板,P CR扩增
HPV 16E6全长基因,PCR产物直接测序或克隆后测序,14个E6分
离片断的测序和序列分析表明,7个(50%)分离株E6基因与原型相
同,5个(35.71%)分离株发生了L83V突变;2个(14.29%)分离株
发生了L83V/D63E突变,HPV16E6原型和L83V突变型在宫颈癌组
织中的分布与其在北美洲的分布接近。对FQ·PCR反应结果中p一actin
阳性的宫颈不同病变组织中HPV16E6阳性率及其相对含量进行统计
分析,宫颈癌蜡块组织59例,HPV 1 6E6阳性率83 .05%;宫颈上皮内
瘤变(CIN)蜡块组织65例,HPV16E6阳性率75.68%;宫颈炎蜡块
组织33例,HPV 1 6E6阳性率93 .33%,宫颈脱落细胞标本%例,
HpV 1 6E6阳性率3 .29%。pCR及F
Objective: Cervical cancer is associated with infections by "high-risk" human papillomavirus(HPVs), HPV16 is the most frequent type. In order to detect HPV16 DNA in cervical carcinomas specimens in Xinjiang uygur. Established a method for detection of HPV16 E6 DNA in paraffin-embedded cervical carcinomas specimens. HPV16E6 has some variants, each with a different geographic distribution. The southern of Xinjiang is one region of the high incidence of cervical cancer, we have reported the variant of HPV16E6 from cervical carcinoma biopsies in Xinjiang Uygur women. This study was designed to investigate distribution of the variant in the cervical cancer of Xinjiang Uygur women, and the relationship between the variant and the high incidence of cervical cancer in Xinjiang. To establish a method of FQ-PCR (fluorescence quantitative PCR ) for detection of HPV16E6 and HPV16 E7 gene in cervical carcinomas and other cervical specimens. To study the relationship between the quantities of HPV16E6 and HPV16 E7 in cervical tissues and the course of cervical disease in Xinjiang. Utilizing HPV16E7 and HPV16E6 gene of a Chinese Uygur patient of cervical carcinoma in Xinjiang, we induced HPV16E7 and HPV16E6 protein expressed in a prokaryotic system and have obtained this
purified protein by affinity chromatography and quantification. The worldwide results have clearly shown that virtually all cervical cancer is caused by human papillomavirus infection. In order to establish fast, sensitive and cost effective method to detect HPV 16 sequences in cervical cancer, we used a visualization of aggregating gold-labeled nanoparticle probe enhanced with silver staining after sequence specific hybridizations.Methods: DNA extraction from archival formalin-fixed and paraffin-embedded specimens was performed by using a standard protocal. HPV16E6 gene was detected by PCR in tissues of 59 cervical cancer, 65 cervical intraepithelial neoplasia (CIN), 33chronic cervicitis in paraffin-embedded specimens and 96 cervical smear samples of vaginitis and cervicitis. DNA was extracted from 19 cervical carcinoma biopsies in Xinjiang Uygur women. HPV16E6 genes were amplified by PCR from the cervical carcinoma tissues. Nucleotide sequences of the HPV16E6 genes were determined by direct or cloning sequencing methods. Analysis the mutations of HPV 16 type E6 gene. The number of copies of HPV16E6 gene and β -actin was detected in parallel by FQ-PCR in tissues of 69 cervical cancer, 65 cervical intraepithelial neoplasia (CIN), 33chronic cervicitis and 96 cervical smear samples of vaginitis and cervicitis. The variation in HPV copies per genomic DNA equivalent can be estimated by dividing the HPV copy number by the β -actin copy number. The number of copies of HPV 16 E7 gene and β -actin was detected in parallel by FQ-PCR in the same tissues. In this experiment, we used the pGEX vetor of 2T-HPV16E7 to transform into E.Coli BL21(DE3), and induced by 0.1 mM IPTG to express GST-HPV16E7 fusion protein. And then the extract bacterial supernatants were purified by affinity chromatography. A450bp HPV16E6 DNA fragment was amplified by using primers designed from the coding sequence of HPV16E6 gene by PCR. The fragment containing the coding sequence of HPV16E6 protein
was cloned into vector pMD-18T (pMD-T-HPV16E6) and transformed into E.coli JM109. Positive clone was identified successfully by enzyme digestion. Detection of HPV 16 sequences in cervical cancer with visualizing nanoparticle probes technology.Gold nanoparticle conjugated at 3'-end of SH-derivative oligonucleotide served as a detection probe, and a 5'-end NH2-derivative oligonucleotide immobili zed on glass surface as a capturing probe. Target DNA was hybridized with both of the capturing probe and the detection probe visualized based on highly sensitive "nano-amplification" and silver staining.Results: The detecting efficiency depended on DNA quality. Of 59 cervical carcinoma cases, all showed positive result of β -actin .The HPV16E6 positive rate was 83.1% (The 49 in 59 cases can be detected possitivel
新猎医科大学博士学位论文
因(HPV 1 6E6)扩增片断,再与互补的纳米金颗粒标记的探针结合,
通过银染加强显色,初步建立了金标银染法快速检测HPv 1 6E6 DNA
的技术。从而为新疆妇女宫颈癌病因研究及宫颈癌的预防、诊断及治
疗的研究提供科学的理论依据。
方法:从浸泡在福尔马林的宫颈癌组织(10例)及福尔马林浸泡后
石蜡包埋的宫颈癌(59例)、宫颈上皮内瘤变(eervical intraepithelial
neoplasia,CIN65例)及宫颈炎(33例)组织中提取DNA;另外对一批
妇科门诊患者(96例)随机取宫颈管的脱落细胞及分泌物,作为对照,
用聚合酶链式反应(PCR)检测各组宫颈组织中人乳头瘤病毒16型
E6基因(HPV 1 6E6)。从19份新疆维吾尔族妇女宫颈癌活检组织标本
中提取组织DNA,作为模板,PCR扩增HPV 1 6E6全长基因,PCR产
物直接测序或克隆后测序,分析新疆维吾尔族妇女宫颈癌组织
HPV16E6基因的突变。以新疆妇女宫颈不同病变组织为源材料,以人
乳头瘤病毒16型(新疆株)E6基因(HpV 1 6E6,AF327851)及HPvl6E7
基因作为扩增的靶基因,同时以人p一actin基因片段作为内参照,借
助于设计的目的基因引物,两个特异的荧光探针,在筛选的FQ一PCR
优化反应体系中,同时对两个基因片段进行扩增,得到HPV 1 6E6及
HPV 1 6E7基因的相对含量。使用本实验室从新疆维吾尔族妇女宫颈癌
组织中克隆的人乳头瘤病毒16型的E7基因(HPV16E7),以pGEX一ZT
载体和大肠杆菌BL21(DE3)原核蛋白表达系统表达HPV16E7融合蛋
白(GST,HPV16E7),经亲和纯化定量后得到大量的GsT一HPv16E7融
和蛋白。根据HPV 16(新疆株)E6基因编码序列设计引物,从含有
HPV 1 6E6基因的质粒中扩增出含HPV 1 6E6基因的DNA片段,将所
得片段与pMD 18一T载体连接,转化到JM109大肠杆菌中,筛选的阳
性克隆扩增后,提取质粒DNA,酶切,回收目的片段,定向克隆到
PET28a中,转化JM109受体菌,从JM109受体菌中提出质粒,再转
化到BLZI(DE3)中,筛选出转化体,用IPTG诱导表达,在PAGE上
见到所表达的18kD的特异性的HPv16(新疆株)E6蛋白条带。从而为
人乳头瘤病毒16型的诊断、检测、疫苗研制等方面的研究提供了物质
基础。研究采用固定于硅烷化片基上的捕获探针,特异性结合单链人
一2一
中文摘要
乳头瘤病毒16型新疆株E6基因(HPV 1 6E6)扩增片断,再与互补的
纳米金颗粒标记的探针结合,通过银染加强显色,初步建立了金标银
染法快速检测HPV16E6 DNA的技术,同时辅以Real一time定量PCR、
地高辛斑点杂交进行平行比较和评价,确认了金标银染法检测的有效
性。
结果:PCR结果宫颈癌蜡块组织59例中HPv16E6阳性37例(阳
性率62.7%);宫颈上皮内瘤变(cIN)组织65例中HPv16E6阳性37
例(阳性率56.92%);石蜡包埋宫颈炎组织共33例,HPV16E6阳性
22例(阳性率“.67%);而宫颈管脱落细胞及分泌物共%例,HPV16E6
阳性3例(阳性率3.13%)。荧光定量PCR结果宫颈癌蜡块组织59例
p一actin均阳性,证实DNA提取方法可靠。从19份新疆维吾尔族妇
女宫颈癌活检组织标本中提取组织DNA,作为模板,P CR扩增
HPV 16E6全长基因,PCR产物直接测序或克隆后测序,14个E6分
离片断的测序和序列分析表明,7个(50%)分离株E6基因与原型相
同,5个(35.71%)分离株发生了L83V突变;2个(14.29%)分离株
发生了L83V/D63E突变,HPV16E6原型和L83V突变型在宫颈癌组
织中的分布与其在北美洲的分布接近。对FQ·PCR反应结果中p一actin
阳性的宫颈不同病变组织中HPV16E6阳性率及其相对含量进行统计
分析,宫颈癌蜡块组织59例,HPV 1 6E6阳性率83 .05%;宫颈上皮内
瘤变(CIN)蜡块组织65例,HPV16E6阳性率75.68%;宫颈炎蜡块
组织33例,HPV 1 6E6阳性率93 .33%,宫颈脱落细胞标本%例,
HpV 1 6E6阳性率3 .29%。pCR及F
Objective: Cervical cancer is associated with infections by "high-risk" human papillomavirus(HPVs), HPV16 is the most frequent type. In order to detect HPV16 DNA in cervical carcinomas specimens in Xinjiang uygur. Established a method for detection of HPV16 E6 DNA in paraffin-embedded cervical carcinomas specimens. HPV16E6 has some variants, each with a different geographic distribution. The southern of Xinjiang is one region of the high incidence of cervical cancer, we have reported the variant of HPV16E6 from cervical carcinoma biopsies in Xinjiang Uygur women. This study was designed to investigate distribution of the variant in the cervical cancer of Xinjiang Uygur women, and the relationship between the variant and the high incidence of cervical cancer in Xinjiang. To establish a method of FQ-PCR (fluorescence quantitative PCR ) for detection of HPV16E6 and HPV16 E7 gene in cervical carcinomas and other cervical specimens. To study the relationship between the quantities of HPV16E6 and HPV16 E7 in cervical tissues and the course of cervical disease in Xinjiang. Utilizing HPV16E7 and HPV16E6 gene of a Chinese Uygur patient of cervical carcinoma in Xinjiang, we induced HPV16E7 and HPV16E6 protein expressed in a prokaryotic system and have obtained this
purified protein by affinity chromatography and quantification. The worldwide results have clearly shown that virtually all cervical cancer is caused by human papillomavirus infection. In order to establish fast, sensitive and cost effective method to detect HPV 16 sequences in cervical cancer, we used a visualization of aggregating gold-labeled nanoparticle probe enhanced with silver staining after sequence specific hybridizations.Methods: DNA extraction from archival formalin-fixed and paraffin-embedded specimens was performed by using a standard protocal. HPV16E6 gene was detected by PCR in tissues of 59 cervical cancer, 65 cervical intraepithelial neoplasia (CIN), 33chronic cervicitis in paraffin-embedded specimens and 96 cervical smear samples of vaginitis and cervicitis. DNA was extracted from 19 cervical carcinoma biopsies in Xinjiang Uygur women. HPV16E6 genes were amplified by PCR from the cervical carcinoma tissues. Nucleotide sequences of the HPV16E6 genes were determined by direct or cloning sequencing methods. Analysis the mutations of HPV 16 type E6 gene. The number of copies of HPV16E6 gene and β -actin was detected in parallel by FQ-PCR in tissues of 69 cervical cancer, 65 cervical intraepithelial neoplasia (CIN), 33chronic cervicitis and 96 cervical smear samples of vaginitis and cervicitis. The variation in HPV copies per genomic DNA equivalent can be estimated by dividing the HPV copy number by the β -actin copy number. The number of copies of HPV 16 E7 gene and β -actin was detected in parallel by FQ-PCR in the same tissues. In this experiment, we used the pGEX vetor of 2T-HPV16E7 to transform into E.Coli BL21(DE3), and induced by 0.1 mM IPTG to express GST-HPV16E7 fusion protein. And then the extract bacterial supernatants were purified by affinity chromatography. A450bp HPV16E6 DNA fragment was amplified by using primers designed from the coding sequence of HPV16E6 gene by PCR. The fragment containing the coding sequence of HPV16E6 protein
was cloned into vector pMD-18T (pMD-T-HPV16E6) and transformed into E.coli JM109. Positive clone was identified successfully by enzyme digestion. Detection of HPV 16 sequences in cervical cancer with visualizing nanoparticle probes technology.Gold nanoparticle conjugated at 3'-end of SH-derivative oligonucleotide served as a detection probe, and a 5'-end NH2-derivative oligonucleotide immobili zed on glass surface as a capturing probe. Target DNA was hybridized with both of the capturing probe and the detection probe visualized based on highly sensitive "nano-amplification" and silver staining.Results: The detecting efficiency depended on DNA quality. Of 59 cervical carcinoma cases, all showed positive result of β -actin .The HPV16E6 positive rate was 83.1% (The 49 in 59 cases can be detected possitivel
引文
[1] Herrington CS. Human papillomaviruses and cervical neoplasia. I. Classification, virology, pathology and epidemiology[J]. Clin Pathol, 1994,47(12): 1066-1069
[2] 王立顺.高危型HPV相关宫颈癌发生及其预防与治疗疫苗[J].中国肿瘤生物治疗杂志,1999,6(1):68-72
[3] Herrington CS. Human papillomaviruses and cervical neoplasia. Ⅱ. Intera-tion of HPV with other factors[J]. Clin Pathol, 1995,48(1): 1-6
[4] 石敏,贺又娥.HPV感染与子宫颈病变的关系及其诊治现状[J].国外医学妇产科学分册,1997,24(5):284-286
[5] 李洁,刘宝印,Zur Hausen等.中国妇女宮颈癌组织中人乳头瘤病毒感染极其地理分布的调查[J].中国实验和临床病毒学,1996,10(1):50-55
[6] 李庭芳,古丽娜·库尔班,王涛等.新疆伽师县夏普桃勒乡妇女子宫颈癌防治的研究[J].新疆医学院学报 1996,19(3):199-203
[7] 拉莱·苏祖克,古丽娜·库尔班,Amy E.Noffersinger等.维吾尔妇女子宫颈癌中p53基因的表达和HPV DNA检测研究[J].新疆医学院学报,1997,20(2):77-81
[8] Walboomers J MM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer world wide [J]. J Pathol, 1999,189:12-19
[9] VonKncbel Doeberitz M, Otersdprf T, Schwartz E, et al. Correlation of modified human papillomavirus early gene expression with altered growth properties on C41 cervical carcinoma cells. [J].Cancer Research, 1988,48: 3780-3786
[10] Biogsiewicz LK, Fiander A, Nimalo M, et al. A recombinant vaccinia virus encoding human papillomavirus type 16 and 18, E6 and E7 proteins as immunotherapy for cervical cancer[J]. Lancet, 1996,347:1523-1527
[1
[11] 郎景和.迎接子宫颈癌预防的全球挑战与机遇[J].中华妇产科杂志,2002,37(3):129
[12] Walboomers JMM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide [J]. J Pathol, 1999,189:12-19
[13] Rozendaal L, Walboomers JMM, van der Linden JC, et al. PCR-based high risk HPV test in cervical cancer screening gives objective risk assessment of women with cytomorphologically normal cervical smears[J]. Int J Cancer, 1996, 68: 766-769
[14] Remmink AJ, Walboomers JMM, Helmerhorst TJM, et al. The presence of persistent high-risk HPV genotypes in dysplastic cervical lesions is associated with progressive disease: natural history up to 36 months[J]. Int J Cancer, 1995,61:306-311
[15] Nobbenhuis MAE, Walboomers JMM, Helmerhorst TJM, et al. Relation of human papillomavirus status to cervical lesions and consequences for cervical-cancer screening: a prospective study[J]. Lancet, 1999,54(9172): 20-25
[16] Holowaty, P., A. B. Miller, T. Rohan, et al. Natural dysplasia of the uterine cervix. J. Natl. Cancer Inst, 1999,91:252-258
[17] Wright, T. C., and IL T. Kurman. A critical review of the morphologic classification system of preinvasive lesions of the cervix: the scientific basis for shifting the paradigm. Papillomavirus Rep. 1994,S:175-182
[18] Kiviat, N. B., and L. A. Koutsky. Specific human papillomavirus types as the causal agents of most cervical intraepithelial neoplasia: implications for current views and treatment. J. Natl. Cancer Inst. 1993,85:934-935
[19] Spitzer, M. Cervical screening adjuncts: recent advances. Am. J. Obstet. Gynecol. 1998,179:544-556
[20] Bedell, M.A., J.B.Hudson, T.R.Goub, et al. Amplification of human papillomvirusgenomes in vitro is dependent on epithelial differentiation J.Virol. 1991,65:2254-2260
[21] Burk, R.D., P.Kelly, J.Feldman, et al. Declining presence of cervicovaginal human papillomavirus infection with age is independent of other risk factors.Sex.Transm.Dis. 1996,23:333-341
[22] Matsukura, T., and M. Sugase. Molecular cloning of a novcl human papillomavirus (type 58) from an invasive cervical carcinoma. Virology. 1990,177:833-836
[23] Roden, R. B., D. R. Lowy, and J. T. Schiller. Papillomavirus is resistant to dessication. J. Infect. Dis. 1997,176:1076-1079
[24] Torrisi, A., A. Del Mistro, G. L. Onnis, et al. Colposcopy, cytology and HPV testing in HIV-positive and HIV-negative women. Eur. J. Gynecol. Oncol. 2000,21:168-172
[25] Solomon, D, M. Schilfman, and R Tarone. Comparison of three management strategies for patients with atypical squamous cells of undetermined significance. Baseline results from ti randomized trial. J. Natl. Cancer Inst. 2001,93:293-299
[26] The Atypical Squamous Cells of Undetermined Sigmificance/Low Grade Squamous iniraepithellal Lesions Triage Study (ALTS) Group. Hu-man papiliomavirus testing for triage of women with cytologic evidence of low-grade squamous intraepithelial lesions: baseline data from a random-ized triM. J. Natl. Cancer Inst. 2000,92: 397-402
[27] Ronnett, B. M, M. M. Manos, J. E. Ransley, et al. Atypical glandular cells of undetermined significance (AGUS): cytopath- ologic fea-tures, histopathologic results, and human papiilomavirus DNA detection. Hum. Pathol. 1999,30:816-825
[28] bson EM, Heid CA, Williams PM. A novel method for real-time quantitative RT-PCR[J]. GenomeRes, 1996,6(8):995-1001
[29] id CA, Stevens J, Livak KJ, et al. Real time quantitative PCR [J]. Genome Res, 1996,6(8):986 -994
[30] DEsjardin LE, chen Y, Perkins MD, et al. Comparison of the ABI 7700 system(TaqMan) andcompititive PCR for quantification of IS 6110 DNA in sputum during treatment of tuberculosis [J].JClin Microbil, 1998,36(7): 1964-1968
[31] Agnetha Josefsson, Ken Livak and Ulf gyliensten. Detection and Quantitation of human papillomavirus by using the fluorescent 5' exonuclease assay. [J]. J of Clinical Microbiology, 1999,3:490-496
[32] Debbie Saslow, PhD, Carolyn D. Runowicz, MD, Diane Solomon, MD. et al. American Cancer Society Guideline for the Early Detection of Cervical Neoplasia and Cancer[J]. CA Cancer J Clin, 2002,52:342-362
[33] Kristine M. Zanotti, MD and Jerome Belinson, MD. Update on the diagnosis and treatment of human papillomavirus infection. [J]. Cleveland Clinic Journal of Medicine, 2002,69(12):948-961
[34] Donna Hubbard McCree Ph. D., M.P.H., R.Ph., Jami S. Leichliter Ph.D. et al. National survey by specialty of U.S. physicians' HPV screening practices . [J] Preventive Medicine, 2003,36(2): 159-163
[35] Howe JR, Klimstra DS, Cordon-CardoC. DNA extraction from paraffinembedded tissues using a salting-out procedure: a reliable method for PCR amplification of archival material[J]. Hisopathol, 1997,12(3):595-601
[36] enny Almog, M.D., Ronni Gamzu, M.D.,Michael J. Kuperminc,M.D. et al. Human papiloma Virus Testing in patient follow-up post cone biopsy due to high-grade cervical intraepithelial neoplasia. [J]Gynecologic Oncology, 2003,88:345-350
[37] Nathalie Ylitalo, Agnetha Josefeen, Mads Melbye et al. A Prospective Study Showing Long-term infection with Human papillomavirus 16 before the Development of Cervical Carcinoma in situ[J]. Cancer Research, 2000, 60(11):6027-6032
[3
[38] Rozendaal L, Walboorners JMM, Vander Linden JC, et al. PCR-based high risk HPV test in cervical cancer screening gives objective risk assessment of women with cytomorpho-logically normal cervical smears. Int J cancer, 1999,68:766-769
[39] Agnetha Josefsson,Ken Livak and Ulf gyliensten. Detection and Quantitation of human papillomavirus by using the fluorescent 5' exonuclease assay. [J]. J of Clinical Microbiology, 1999, 3:490-496
[40] 从娟,张清元,李建民等,PCR检测技术中石蜡包埋组织DNA提取方法的比较.肿瘤研究与临床,1999,11(2):86
[41] 张金生,刘鸿瑞.两种提取石蜡包埋组织DNA方法的比较.诊断病理学杂志,2000,7(2):83
[42] Gibson EM, Heid CA, Williams PM. A novel method for real time quantitative RT-PCR [J]. Genome Res, 1996,6(8):995-1001
[43] Heid CA, Stevens J, Livak KJ, et al. Real time quantitative PCR [J]. Genome Res, 1996,6(8):986-994
[44] DEsjardin LE, chen Y, Perkins MD, et al. Comparison of the ABI 7700 system(TaqMan) and compititive PCR for quantification of IS 6110 DNA in sputum during treatment of tuberculosis[J].J Clin Microbil, 1998,36(7): 1964-1968
[45] Agnetha Josefsson, Ken Livak and Ulf gyliensten. Dectection and Quantitation of human papillomavirus by using the fluorescent 5' exonuclease assay. [J]. J of Clinical Microbiology, 1999,3:490-496
[46] Clifford GM, Smith JS, Plummer M, et al. Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis [J]. British Journal of Cancer, 2003,88:63-73
[47] Hwang TS, Jeong JK, Park M, et al. Detection and typing of HPV genotypes in various cervical lesions by HPV oligonucleotide microarray [J]. Gynecologic Oncology, 2003,90:51-56
[48] Yamada T, Manos MM, Peto J, et al. Human Papillomavirus Type 16 Sequence Variation in Cervical Cancers: a Worldwide Perspective [J]. J. Virol. 1997,71:2463-2472
[49] Yamada T, Wheeler CM, Halpern AL. et al. Human papillomavirus type 16 variant lineages in United States populations characterized by nucleotide sequence analysis of the E6, L2, and L1 coding segments [J]. J. Viral. 1995, 69:7743-7753
[50] Walboomers J MM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer world wide [J]. J Pathol, 1999,189:12-19
[51] Nobbenhuis MAE, Walboomers JMM, Helmerhorst TJM, et al. Relation of human papillomavirus status to cervical lesions and consequences for cervical-cancer screening: a prospective study[J]. Lancet, 1999,54(9172): 20-25
[52] 马正海,钱东,马纪,等.中国新疆维吾尔妇女宫颈瘤组织中乳头状瘤病毒16型E6基因的克隆和序列分析[J].生物化学与生物物理进展,2001,38(3):399-404
[53] Seedorf K, Kraemmer G, Duerst M, et al. Human papillomavirus type 16 DNA sequence [J]. J Virol, 1985,145:181-185
[54] Mayrand MH, Coutlee F, Hankins C. et al. Detection of Human Papillomavirus Type 16 DNA in Consecutive Genital Samples Does Not Always Represent Persistent Infection as Determined by Molecular Variant Analysis [J]. J. Clin. Microbiol. 2000,38:3388-3393
[55] Berumen J, Ordonez RM, Lazcano E, et al. Asian-American Variants of Human Papillomavirus 16 and Risk for Cervical Cancer: a Case-Control Study [J]. J. Natl. Cancer Inst. 2001,93:1325-1330
[56] Swan DC, Tucker RA, Tortolero-Luna G. et al. Human papillomavirus (HPV) DNA copy number is dependent on grade of cervical disease and HPV type [J]. J. Clin. Microbiol, 1999,37: 1030-1034
[57] Matsumoto K, Yoshikawa H, Nakagawa S, et al. Enhanced oncogenicity of human papillomavirus type 16 (HPV16) variants in Japanese population [J]. Cancer Letters, 2000,156:159-165
[58] Londesborough P, Ho L, Terry G, et al. Human papillomavirus genotype as a predictor of persistence and development of high-grade lesions in women with minor cervical abnormalities [J]. Int J Cancer 1996;69:364-8
[59] Zehbe I, Wilander E, Delius H, et al. Human papillomavirus 16 E6 variants are more prevalent in invasive cervical carcinoma than the prototype [J]. Cancer Res 1998;58:829 -33
[60] Zehbe I, Voglino G, Wilander E, et al. p53 codon 72 polymorphism and various human papillomavirus 16 E6 genotypes are risk factors for cervical cancer development [J]. Cancer Res 2001;61:608-11
[61] Zehbe I, Voglino G, Delius H, et al. Risk of cervical cancer and geographical variations of human papillomavirus 16 E6 polymorphisms [J]. Lancet 1998;352:1441-2
[62] Zehbe I, Tachezy R, Mytilineos J, Human papillomavirus 16 E6 polymorphisms in cervical lesions from different European populations and their correlation with human leukocyte antigen class II haplotypes [J]. Int. J. Cancer, 2001,94:711-716
[63] Matsumoto K, Yasugi, Nakagawa S, Human papillomavirus 16 E6 variants and HLA class II alleles among Japanese women with cervical cancer [J]. Int. J. Cancer, 2003,106:919-922
[64] Debbie Saslow, PhD, Carolyn D. Runowicz, MD, Diane Solomon, MD. et al. American Cancer Society Guideline for the Early Detection of Cervical Neoplasia and Cancer [J]. CA Cancer J Clin, 2002,52:342-362
[65] Kristine M. Zanotti, MD and Jerome Belinson, MD. Update on the diagnosis and treatment of human papillomavirus infection. [J]. Cleveland Clinic Journal of Medicine,2002, 69(12):948-961
[6
[66] Donna Hubbard McCree Ph.D., M.P.H., R.Ph., Jami S. Leichliter Ph.D. et al. National survey by specialty of U.S. physicians' HPV screening practices. [J] Preventive Medicine, 2003,36(2): 159-163
[67] Samutl Ratnam, Eduardo L. Franco, and Alex Ferenczy. Human papillomavirus Testing for Primary Screening of Cervical Cancer Precursors. [J] Cancer Epidemiology, 2000,9(9):945-951
[68] Romanczuk H, Vill L, Schlegel R. et al. The viral transcriptional regulatory region upstream of the E6 and E7 gene is a major determinant of the differential immortalization activities of human papillomavirus types 16 and 18. J Virol, 1991,65:2739-2743
[69] 马正海,钱东,马纪,等.新疆维吾尔族妇女宫颈癌组织中乳头瘤病毒16型E6基因的克隆和序列分析.生物化学与生物物理进展,2001,28(3):400-404
[70] 徐来祥,张知彬,宋铭晶,等.福尔马林保存的动物标本基因组DNA的提取方法.动物学报,2002,48(2):264-269
[71] Bosch FX, Manos MM, Mu(?)oz N, et al. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) study group. Journal of the National Cancer Institute, 1995,87(11):796-802
[72] Trofatter, K. F. Diagnosis of human papillomavirus genital tract infection. Am. J. Med., 1997,102:21-27
[73] Gibson EM, Heid CA, Williams PM. A novel method for real-time quantitative RT-PCR [J]. GenomeRes, 1996,6(8):995-1001
[74] Heid CA, Stevens J, Livak KJ, et al. Real time quantitative PCR [J]. Genome Res, 1996,6(8):986-994
[75] DEsjardin LE, chen Y, SD Perkins MD, et al. Comparison of the ABI 7700 system(TaqMan) andcompititive PCR for quantification of IS 6110 DNA in sputum during treatment of tuberculosis [J]Clin Microbil, 1998,36(7):1964-1968
[76] Agnetha Josefsson, Ken Livak and Ulf gyliensten. Detection and Quantitation of human papillomavirus by using the fluorescent 5' exonuclease assay. [J]. J of Clinical Microbiology , 1999,3:490-496
[77] Jin, X. W., J. Cash, and A. W. Kennedy. Human papillomavirus typing and the reduction of cervical cancer risk. Cleveland Clin. J. Med. 1999,66: 533-539
[78] Benny Almog, M.D., Ronni Gamzu, M.D., Michael J. Kuperminc, M.D. et al. Human papiloma Virus Testing in patient follow-up post cone biopsy due to high-grade cervical intraepithelial neoplasia. [J]Gynecologic Oncology, 2003,88:345-350
[79] Nathalie Ylitalo, Agnetha Josefeen, Mads Melbye et al. A Prospective Study Showing Long-term infection with Human papillomavirus 16 before the Development of Cervical Carcinoma in situ. [J]Cancer Research, 2000,60(11):6027-6032
[80] Rozendaal L, Walboorners JMM, Vander Linden JC, et al. PCR-based high risk HPV test in cervical cancer screening gives objective risk assessment of women with cytomorpho-logically normal cervical smears. Int J cancer, 1999,68:766-769
[81] Nathalie Ylitalo, Agnetha Josefeen, Mads Melbye et al. A Prospective Study Showing Long-term infection with Human papillomavirus 16 before the Development of Cervical Carcinoma in situ[J]. Cancer Research, 2000,60(11):6027-6032
[82] zur Elausen, H. Papiilomaviruses in human cancers. Proc. Assoc. Am. Physicians. 1999,111:581-587
[83] Jin, X. W., J. Cash, and A. W. Kennedy. Human papillomavirus typing and the reduction of cervical cancer risk. Cleveland Clin. J. Med. 1999,66:533-539
[84] Walboomers, J.M.M., M.V.Jacobs, M.M.Manos, et al. human papillomavirus is a necessary cause of invasive cervical cancer worldwide, j. pathol. 1999,189:12-19
[85] Andersson, S., E. Rylander, B.Larsson, A.Strand, et al. The role of human papillomavirus in cervical adenocarcnoma carcinogenesis. Eur.J.Cancer, 2001,37:246-250
[86] Calore, E.E., S.M.M.Pereira,and M.J.Cavaliere. Progression of cervical lesions in HIV-seropositive woman:a cytological study. Diagn. Cytopathol. 2001,24:117-119
[87] Heid CA, Stevens J, Livak KJ, et al. Real time quantitative PCR [J]. Genome Res, 1996,6(8):986-994
[88] DEsjardin LE, chen Y,SD Perkins MD, et al. Comparison of the ABI 7700 system(TaqMan) andcompititive PCR for quantification of IS 6110 DNA in sputum during treatment of tuberculosis [J]Clin Microbil, 1998,36(7): 1964-1968
[89] Harro, C. D., Y.-Y. S. Pang, R B. S. Roden, et al. Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vac-cine. J. Natl. Cancer Inst. 2001,93: 284-292
[90] Jin, X. W., J. Cash, and A. W. Kennedy. Human papillomavirus typing and the reduction of cervical cancer risk. Cleveland Clin. J. Med. 1999,66: 533-539
[91] Franco, E. L. Cancer causes revisited:human papillomavirus and cervical neoplasia. J. Natl. Cancer Inst. 1995,87:779-780
[92] Beaudenon, S.,D.Kremsdorf, O.Croillant,S.Jabonska, S.WainHobson, and G.Orth. A novel type of human papillomavirus associated with genital neoplasias. Nature, 1986,321:246-249
[93] Beaudenon, S,D.Kremsdorf, S.Obalek,S.Jablonska, G.PehauAmaudet, O.Croillant. Plurality of genital human papillomaviruses: characterization of two new types with distinct bilolgical prpoerties. Virlolgy, 1987,161: 373-384
[94] Bosch, R, M.Manos, N.Munoz, et al. Prevalence of human papillomvirus in cervical: a wordwide perspective. J. Natl. Cancer Inst. 1995, 87:796-802
[95] Fuchs, P. G., F. Girardi, and H. Pfister. Human papillomavirus DNA in normal, metaplastic, preneoplastic and neoplastic epithelia of the cervix uteri. Int. J. Cancer, 1988,41:41-45
[96] Gissmann, L., L. Wolnik, H. Ikenberg, et al. Human papillomavirus types 6 and 11 DNA se-quences in genital and laryngeal papillomas and in some cervical cancers. Proc. Natl. Acad. Sci. USA 1983,80: 560-563
[97] Lonquet, M., S. Beaudenon, and G. Orth. Two novel genital papil-Iomavirus (HPV) types: HPV68 and HPV70, related to the potentially oncogenic HPV39. J. Clin. Microbiol, 1996,34:738-744
[98] Lorincz, A. T., W. D. Lancaster, and G. F. Temple. Cloning and characterization of the DNA of a new human papillomavirus from a woman with dysplasia of the uterine cervix. J. Virol, 1986,58:225-229
[99] Lorincz, A. T, A. P. Quinn, W. D. Lancaster, and G. F. Temple. A new type of papillomavirus associated with cancer of the uterine cervix. Virology 1987,159:.187-190
[100]Lorincz, A. T, G. F. Temple, R J. Kurman, A. B. Jenson, and W. D. Lancaster. Oncogenic association of specific human papillomavirus types with cervical neoplasia. JNCI, 1987,79:671-677
[101]Lorincz, A. T., A. P. Quinn, M. D. Goldsborough, P. McAllister, and G. F.Temple. Human papillomavirus type 56: a new virus detected in cervical cancers. J. Gen. Virol. 1989,70:3099-3104
[102]Lorincz, A. T, A, P. Quinn, M. D. Goldsborough, B. J. Schmidt, and G. F. Temple. Cloning and partial DNA sequencing of two new human papillomavirus types associated with condylomas and! owgrade cervical neoplasia. J. Virol. 1989,63:2829-2834
[103]Lorincz, A. T, and IL Reid. Association of human papillomavirus with gynecological cancer. Curr. Opin. Oncol. 1989,1:123-132
[104]Lorincz, A. T, R. Reid, A. B. Jenson, M. D. Greenberg, W. Lancaster, and R. J. Kurman. Human papillomavirus infection of the cervix: relative risk associations of 15 common anogenital types. Obstet. Gynecol. 1992,79:328-337
[105]Manos, M. M., W. K. Kinney, L. B. Hurley, M. E. Sherman, J. Shieh-Ngai, R. J. Sherman, J. E. Ramsey, B. J. Fetterman, J. S. Hartinger, K. M. Mclntosh, G. F. Pawlik, and R. A. Htiatt. Identifying women with cervical neoplasia: Using human papillomavirus DNA testing for equivocal Papanicolaou results. JAMA 1999,281:1605-1610
[106]Munoz, N, F. X. Bosch, K. V. Shah, and A. Meheus. The epide-miology of cervical cancer and human papillomavirus. Scientific Publication 119. International Agency for Research on Cancer, Lyon, France, 1992
[107]Naghashfar, Z. S., N. B. Rosenshein, A. T. Lorincz, J. Buscema, and K. V. Shah. Characterization of human papillomavirus type 45, a new type 18-related virus of the genital tract. J. Gen. Virol. 1987,68: 3073-3079
[108]Nuovo, G. J., C, P. Crum, E. M. de Villiers, R. U. Levine, and S. J. Silverstein. Isolation of a novel human papillomavirus (type 51) from a cervical condyloma. J. Virol. 1988,62:1452-1455
[109]Reid, R, M. Greenberg, A. B. Jenson, M. Husain, J. Willett, Y. Daoud, G.Temple, C. R Stanhope, A. L Sherman, G. D. Phibbs, and A. T. Lorincz. Sexually transmitted papillomavirus infections. 1. The anatomic dis-tribution and pathogenic grade of neoplastic lesions associated with differ-ent viral types. Am. J. Obstet. Gynecol. 1987,156:212-222
[110]Rho, J. A. Roy-Burman, H. Kim, E. M. de Villiers, T. Matsukura, and J. Choe. Nucleotide sequence and phyiogenetic classification of hu-man papillomavirus type 59. Virology 1994,203:158- 161
[111]Shimoda, K., A. T. Losrincz, F. Temple, and W. D. Lancaster. Human papillomavirus type 52: a new virus associated with cervical neoplasia. J. Gen. Virol. 1988,69:2925-2928
[112]Swan, D. C, R. A. Tucker, G. Tortolero-Luna, et al. Human papilloma (HPV) DNA copy number is dependent on grade of cervical disease and HPV type. J. Clin. Microbiol. 1999,37:1030-1034
[113]Giannoudis, A., and C. S. Herrington. Human papillomavirus variants and squamous neoplasia of the cervix. J. Pathol. 2001,192: 395-302
[114]Quint, W. G. V, G. Scholte, L. J. Van Doom, et al. Comparative analysis of human papillomavirus infections in cervical scrapes and biopsy specimens by general SPF10 PCR and HPV genotyping. J. Pathol. 2001,194:51-57
[115]Schiffman, M., R. Herrero, A. Hildesheim, et al. HPV DNA testing in cervical cancer screening. Results from women in a high-risk province of Costa Rica. 2000,JAMA 283:87-93
[116]Nobbenhuis, M. A., C. J. Meijer, A. J. van den Brule, et al. Addition of high-risk HPV testing improves the current guidelines onfollow-up after treatment for cervical intraepithelial neoplasia. Br.j. cancer8, 2001,4:796-801
[117]Bosch FX, Manos MM, Munoz N, et al. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) study group. Journal of the National Cancer Institute, 1995,87(11):796-802
[118]Bosch, F., M.Manos, N.Munoz, et al. Prevalence of human papillomvirus in cervical:a wordwide perspective. J. Natl. Cancer Inst. 1995,87:796-802
[119]Swan, D. C, R. A. Tucker, G. Tortolero-Luna, M. F. Mitchell, L. Wideroff, E. R. Unger, R. A. Nisenbaum, W. C. Reeves, and J. P. Icenogle. 1999
[120]Zerbini, M., S. Venturoli, M. Cricca, G. Gallinella, P. De Simone, S. Costa, D. Santini, and M. Musiani. Distribution and viral load of type specific HPVs in different cervical lesions as detected by PCR-ELISA. J. Clin. Pathol. 2001,54:377-380
[121]Holowaty, P., A. B. Miller, T. Rohan, et al. Natural dysplasia of the uterine cervix. J. Natl. Cancer Inst. 1999,91:252-258
[122]Wright, T. C, and IL T. Kurman. A critical review of the morphologic classification system of preinvasive lesions of the cervix: the scientific basis for shifting the paradigm. Papillomavirus Rep. 1994,S:175-182
[123]Spitzer, M. Cervical screening adjuncts: recent advances. Am. J. Obstet. Gynecol. 1998,179:544-556
[124]enny Almog, M.D., Ronni Gamzu, M.D.,Michael J. Kuperminc,M.D. et al. Human papiloma Virus Testing in patient follow-up post cone biopsy due to high-grade cervical intraepithelial neoplasia. [J]Gynecologic Oncology, 2003,88:345-350
[125]Nathalie Ylitalo, Agnetha Josefeen, Mads Melbye et al. A Prospective Study Showing Long-term infection with Human papillomavirus 16 before the Development of Cervical Carcinoma in situ[J]. Cancer Research, 2000, 60(11):6027-6032
[126]Rozendaal L, Walboorners JMM, Vander Linden JC, et al. PCR-based high risk HPV test in cervical cancer screening gives objective risk assessment of women with cytomorpho-logically normal cervical smears. Int J cancer, 1999,68:766-769
[127]Nathalie Ylitalo, Agnetha Josefeen, Mads Melbye et al. A Prospective Study Showing Long-term infection with Human papillomavirus 16 before the Development of Cervical Carcinoma in situ. [J]Cancer Research, 2000,60(11):6027-6032
[128]Dalal S, Gao Q, Androphy EJ, et al. Mutational analysis of human papillomavirus type 16 E6 demonstrates that p53 degradation is necessary for immortalization of mammary epithelial cells[J]. Virology, 1996,70(2): 2683-2688
[129]Lebuanec H, Anna RD, Achgar AL, et al. HPV16 E7 but not E6 oncogenic protein triggers both cellular immunosuppression and angiogenic processes [J]. Biomedicine & Pharmacother, 1999,53(4): 424-431
[130]Herrington CS. Human papillomaviruses and cervical neoplasia. II. Interation of HPV with other factors[J]. Clin Pathol 1995,48(1): 1-6
[131]Lebuanec H, Anna RD, Achgar AL, et al. HPV16 E7 but not E6 oncogenic protein triggers both cellular immunosuppression and angiogenic processes [J]. Biomed & Pharmacother. 1999,53(4):424-431
[132]Foster SA, Galloway DA.Human papillomavirus type 16 E7 alleviates aproliferation block in early passage human mammary epithelial cells[J]. Oncogene. 1996,12 (8): 1773-1779
[133]Androphy EJ. Molecular biology of human papillomavirus infection and oncogenesis[J]. Invest Dermatol. 1994,103 (2):248-256
[134]Dalal S, Gao Q, Androphy EJ, et al. Mutational analysis of human papillomavirus type 16 E6 demonstrates that p53 degradation is necessary for immortalization of mammary epithelial cells[J]. Virology, 1996,70(2): 2683-2688
[135]Lebuanec H, Anna RD, Achgar AL, et al. HPV 16 E7 but not E6 oncogenic protein triggers both cellular immunosuppression and angiogenic processes [J]. Biomedicine & Pharmacother, 1999,53(4): 424-431
[136]LowyDR, KimbauerR, SchillerJT. Genitalhumanpa-pillomavirus in fection [J]. ProNatlAcadSciUSA, 1994,91:2436-2440
[137]HausenH, VilliersEM. Humanpapillomavirus[J]. AnnuRevMicrobiol, 1994,4 8:427
[138]SongSY, PitotHC, LambertPF. The human papillomavirus type16E6 gene alone is sufficient to induce carcinomas in transgenic animals [J]. JVirol, 1999,73(7):5887-5893
[139]SeedorfK, KraemmerG, DuerstM, et al. Human papilloma virus type16DNA sequence [J]. JVirol, 1985,145:181-191
[140]Swan DC, Tucker RA, Tortolero-Luna G. et al. Human papillomavirus (HPV) DNA copy number is dependent on grade of cervical disease and HPV type [J]. J. Clin. Microbiol, 1999,37: 1030-1034
[141]Foster SA, Galloway DA. Human papillomavirus type 16 E7 alleviates aproliferation block in early passage human mammary epithelial cells[J]. Oncogene. 1996,12 (8):1773-1779
[142]Storhoff J J, Elghanian R, Mucic R C, et al. "One-Pot Colorimetric Differentiation of Polynucleotides with Single Base Imperfections Using Gold Nanoparticle Probes," J. Am. Chem. Soc, 1998,120, 1959-1964
[143]Taton T A, Mirkin C A, Letsinger R L. "Scanometric DNA Array Detection with Nanoparticle Probes" Science, 2000,289,1757-1760
[144]Park S J, Taton T A, Mirkin C A. "Array-Based Electrical Detection of DNA Using Nanoparticle Probes," Science, 2002,295(5559), 1503-1506
[145]Cao Y C, Jin R, Mirkin CA. Nanoparticles with Raman spectroscopic fingerprints for DNA and RNA detection. Science. 2002,297(5586): 1536-1540
[146]Dyson N, Howley P M, Munger K, et al.The human papilloma virus: 16 E7 oncoprotein is able to the retinoblastoma gene product. Science, 1989,243: 934-937
[147]Hausen H. Papillomavirus infections: a major cause of human cancers. Biochim. Biophys. Acta 1996,1228:F55-F78
[148]Lorincz A T, Reid R, Bennett A, et al. Human papillomavirus infection of the cervix: relative riskassociations of 15 common anogenital types. Obstet. Gynecol. 1992,79:328-337
[1
[149] Scheffner M, Huibregtse J M, Vierstra R D, et al. The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53. Cell, 1993,75:495-505
[150] Trofatter K F. Diagnosis of human papillomavirus genital tract infection. Am. J. Med. 1997,102 (5A): 21-27
[151] Li T F(李庭芳),G μ Lnar K(古丽娜.库尔班),Wang T(王涛),et al. A study on the prevention and therapy of carcinoma of the cervix in xapt μ L township jashi county, xinjiang. Acta Academiae Medicinae Xinjiang(新疆医学院学报),1996,19(3):199～203
[152] Lalai S(拉莱.苏祖克),G μ Lnar K(古丽娜.库尔班),Amy E,et al. Immunostaining of the p53 gene and detection of human papillomavirus in cervical carcinoma of uygur women. Acta Academiae Medicinae Xinjiang(新疆医学院学报),1997,20(2):77-81
[153] Ma ZH H(马正海),Qian D(钱东),Ma J(马纪),et al.Cloning and sequenceing of HPV16E6 gene from cervical carcinoma biopsies in Xinjiang. Prog. Biochem. Biophys(生物化学与生物物理进展).2001,28(3):400-404
[154] Moller R, Csaki A, Kohler JM, et al. DNA probes on chip surfaces studied by scanning force microscopy using specific binding of colloidal gold. Nucleic Acids Research. 2000,28(20):e91
[155] Gravitt P E, Peyton C L,Apple R J, et al. Genotyping of 27 Human Papillomavirus Types by Using L1 Consensus PCR Products by a Single-Hybridization, Reverse Line Blot Detection Method. J Clin Microbiol, 1998,36(10):3020-3027
[156] zur hausen, H. Papiliomavirus infections a major cause of human cancers. Biochim. Biophys. Acta. 1996,1288:55-78
[157] Conrad-Stoppler, M. C., K. Ching, H. Stoppler, et al. Natural variants of the human papillomavirus type 16 E6 protein differ in their abilities to alter keratinocyte differentiation and to induce p53 degradation. J. Virol. 1996,70:6987-6993
[158]Veress, G, K, Szarka, X.-P. Dong, L. Gergely, et al. Func-tional significance of sequence variation in the E2 sene and the long control region of human papillomavirus type 16. J. Gen. Virol. 1999,80: 1053-1043
[2] 王立顺.高危型HPV相关宫颈癌发生及其预防与治疗疫苗[J].中国肿瘤生物治疗杂志,1999,6(1):68-72
[3] Herrington CS. Human papillomaviruses and cervical neoplasia. Ⅱ. Intera-tion of HPV with other factors[J]. Clin Pathol, 1995,48(1): 1-6
[4] 石敏,贺又娥.HPV感染与子宫颈病变的关系及其诊治现状[J].国外医学妇产科学分册,1997,24(5):284-286
[5] 李洁,刘宝印,Zur Hausen等.中国妇女宮颈癌组织中人乳头瘤病毒感染极其地理分布的调查[J].中国实验和临床病毒学,1996,10(1):50-55
[6] 李庭芳,古丽娜·库尔班,王涛等.新疆伽师县夏普桃勒乡妇女子宫颈癌防治的研究[J].新疆医学院学报 1996,19(3):199-203
[7] 拉莱·苏祖克,古丽娜·库尔班,Amy E.Noffersinger等.维吾尔妇女子宫颈癌中p53基因的表达和HPV DNA检测研究[J].新疆医学院学报,1997,20(2):77-81
[8] Walboomers J MM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer world wide [J]. J Pathol, 1999,189:12-19
[9] VonKncbel Doeberitz M, Otersdprf T, Schwartz E, et al. Correlation of modified human papillomavirus early gene expression with altered growth properties on C41 cervical carcinoma cells. [J].Cancer Research, 1988,48: 3780-3786
[10] Biogsiewicz LK, Fiander A, Nimalo M, et al. A recombinant vaccinia virus encoding human papillomavirus type 16 and 18, E6 and E7 proteins as immunotherapy for cervical cancer[J]. Lancet, 1996,347:1523-1527
[1
[11] 郎景和.迎接子宫颈癌预防的全球挑战与机遇[J].中华妇产科杂志,2002,37(3):129
[12] Walboomers JMM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide [J]. J Pathol, 1999,189:12-19
[13] Rozendaal L, Walboomers JMM, van der Linden JC, et al. PCR-based high risk HPV test in cervical cancer screening gives objective risk assessment of women with cytomorphologically normal cervical smears[J]. Int J Cancer, 1996, 68: 766-769
[14] Remmink AJ, Walboomers JMM, Helmerhorst TJM, et al. The presence of persistent high-risk HPV genotypes in dysplastic cervical lesions is associated with progressive disease: natural history up to 36 months[J]. Int J Cancer, 1995,61:306-311
[15] Nobbenhuis MAE, Walboomers JMM, Helmerhorst TJM, et al. Relation of human papillomavirus status to cervical lesions and consequences for cervical-cancer screening: a prospective study[J]. Lancet, 1999,54(9172): 20-25
[16] Holowaty, P., A. B. Miller, T. Rohan, et al. Natural dysplasia of the uterine cervix. J. Natl. Cancer Inst, 1999,91:252-258
[17] Wright, T. C., and IL T. Kurman. A critical review of the morphologic classification system of preinvasive lesions of the cervix: the scientific basis for shifting the paradigm. Papillomavirus Rep. 1994,S:175-182
[18] Kiviat, N. B., and L. A. Koutsky. Specific human papillomavirus types as the causal agents of most cervical intraepithelial neoplasia: implications for current views and treatment. J. Natl. Cancer Inst. 1993,85:934-935
[19] Spitzer, M. Cervical screening adjuncts: recent advances. Am. J. Obstet. Gynecol. 1998,179:544-556
[20] Bedell, M.A., J.B.Hudson, T.R.Goub, et al. Amplification of human papillomvirusgenomes in vitro is dependent on epithelial differentiation J.Virol. 1991,65:2254-2260
[21] Burk, R.D., P.Kelly, J.Feldman, et al. Declining presence of cervicovaginal human papillomavirus infection with age is independent of other risk factors.Sex.Transm.Dis. 1996,23:333-341
[22] Matsukura, T., and M. Sugase. Molecular cloning of a novcl human papillomavirus (type 58) from an invasive cervical carcinoma. Virology. 1990,177:833-836
[23] Roden, R. B., D. R. Lowy, and J. T. Schiller. Papillomavirus is resistant to dessication. J. Infect. Dis. 1997,176:1076-1079
[24] Torrisi, A., A. Del Mistro, G. L. Onnis, et al. Colposcopy, cytology and HPV testing in HIV-positive and HIV-negative women. Eur. J. Gynecol. Oncol. 2000,21:168-172
[25] Solomon, D, M. Schilfman, and R Tarone. Comparison of three management strategies for patients with atypical squamous cells of undetermined significance. Baseline results from ti randomized trial. J. Natl. Cancer Inst. 2001,93:293-299
[26] The Atypical Squamous Cells of Undetermined Sigmificance/Low Grade Squamous iniraepithellal Lesions Triage Study (ALTS) Group. Hu-man papiliomavirus testing for triage of women with cytologic evidence of low-grade squamous intraepithelial lesions: baseline data from a random-ized triM. J. Natl. Cancer Inst. 2000,92: 397-402
[27] Ronnett, B. M, M. M. Manos, J. E. Ransley, et al. Atypical glandular cells of undetermined significance (AGUS): cytopath- ologic fea-tures, histopathologic results, and human papiilomavirus DNA detection. Hum. Pathol. 1999,30:816-825
[28] bson EM, Heid CA, Williams PM. A novel method for real-time quantitative RT-PCR[J]. GenomeRes, 1996,6(8):995-1001
[29] id CA, Stevens J, Livak KJ, et al. Real time quantitative PCR [J]. Genome Res, 1996,6(8):986 -994
[30] DEsjardin LE, chen Y, Perkins MD, et al. Comparison of the ABI 7700 system(TaqMan) andcompititive PCR for quantification of IS 6110 DNA in sputum during treatment of tuberculosis [J].JClin Microbil, 1998,36(7): 1964-1968
[31] Agnetha Josefsson, Ken Livak and Ulf gyliensten. Detection and Quantitation of human papillomavirus by using the fluorescent 5' exonuclease assay. [J]. J of Clinical Microbiology, 1999,3:490-496
[32] Debbie Saslow, PhD, Carolyn D. Runowicz, MD, Diane Solomon, MD. et al. American Cancer Society Guideline for the Early Detection of Cervical Neoplasia and Cancer[J]. CA Cancer J Clin, 2002,52:342-362
[33] Kristine M. Zanotti, MD and Jerome Belinson, MD. Update on the diagnosis and treatment of human papillomavirus infection. [J]. Cleveland Clinic Journal of Medicine, 2002,69(12):948-961
[34] Donna Hubbard McCree Ph. D., M.P.H., R.Ph., Jami S. Leichliter Ph.D. et al. National survey by specialty of U.S. physicians' HPV screening practices . [J] Preventive Medicine, 2003,36(2): 159-163
[35] Howe JR, Klimstra DS, Cordon-CardoC. DNA extraction from paraffinembedded tissues using a salting-out procedure: a reliable method for PCR amplification of archival material[J]. Hisopathol, 1997,12(3):595-601
[36] enny Almog, M.D., Ronni Gamzu, M.D.,Michael J. Kuperminc,M.D. et al. Human papiloma Virus Testing in patient follow-up post cone biopsy due to high-grade cervical intraepithelial neoplasia. [J]Gynecologic Oncology, 2003,88:345-350
[37] Nathalie Ylitalo, Agnetha Josefeen, Mads Melbye et al. A Prospective Study Showing Long-term infection with Human papillomavirus 16 before the Development of Cervical Carcinoma in situ[J]. Cancer Research, 2000, 60(11):6027-6032
[3
[38] Rozendaal L, Walboorners JMM, Vander Linden JC, et al. PCR-based high risk HPV test in cervical cancer screening gives objective risk assessment of women with cytomorpho-logically normal cervical smears. Int J cancer, 1999,68:766-769
[39] Agnetha Josefsson,Ken Livak and Ulf gyliensten. Detection and Quantitation of human papillomavirus by using the fluorescent 5' exonuclease assay. [J]. J of Clinical Microbiology, 1999, 3:490-496
[40] 从娟,张清元,李建民等,PCR检测技术中石蜡包埋组织DNA提取方法的比较.肿瘤研究与临床,1999,11(2):86
[41] 张金生,刘鸿瑞.两种提取石蜡包埋组织DNA方法的比较.诊断病理学杂志,2000,7(2):83
[42] Gibson EM, Heid CA, Williams PM. A novel method for real time quantitative RT-PCR [J]. Genome Res, 1996,6(8):995-1001
[43] Heid CA, Stevens J, Livak KJ, et al. Real time quantitative PCR [J]. Genome Res, 1996,6(8):986-994
[44] DEsjardin LE, chen Y, Perkins MD, et al. Comparison of the ABI 7700 system(TaqMan) and compititive PCR for quantification of IS 6110 DNA in sputum during treatment of tuberculosis[J].J Clin Microbil, 1998,36(7): 1964-1968
[45] Agnetha Josefsson, Ken Livak and Ulf gyliensten. Dectection and Quantitation of human papillomavirus by using the fluorescent 5' exonuclease assay. [J]. J of Clinical Microbiology, 1999,3:490-496
[46] Clifford GM, Smith JS, Plummer M, et al. Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis [J]. British Journal of Cancer, 2003,88:63-73
[47] Hwang TS, Jeong JK, Park M, et al. Detection and typing of HPV genotypes in various cervical lesions by HPV oligonucleotide microarray [J]. Gynecologic Oncology, 2003,90:51-56
[48] Yamada T, Manos MM, Peto J, et al. Human Papillomavirus Type 16 Sequence Variation in Cervical Cancers: a Worldwide Perspective [J]. J. Virol. 1997,71:2463-2472
[49] Yamada T, Wheeler CM, Halpern AL. et al. Human papillomavirus type 16 variant lineages in United States populations characterized by nucleotide sequence analysis of the E6, L2, and L1 coding segments [J]. J. Viral. 1995, 69:7743-7753
[50] Walboomers J MM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer world wide [J]. J Pathol, 1999,189:12-19
[51] Nobbenhuis MAE, Walboomers JMM, Helmerhorst TJM, et al. Relation of human papillomavirus status to cervical lesions and consequences for cervical-cancer screening: a prospective study[J]. Lancet, 1999,54(9172): 20-25
[52] 马正海,钱东,马纪,等.中国新疆维吾尔妇女宫颈瘤组织中乳头状瘤病毒16型E6基因的克隆和序列分析[J].生物化学与生物物理进展,2001,38(3):399-404
[53] Seedorf K, Kraemmer G, Duerst M, et al. Human papillomavirus type 16 DNA sequence [J]. J Virol, 1985,145:181-185
[54] Mayrand MH, Coutlee F, Hankins C. et al. Detection of Human Papillomavirus Type 16 DNA in Consecutive Genital Samples Does Not Always Represent Persistent Infection as Determined by Molecular Variant Analysis [J]. J. Clin. Microbiol. 2000,38:3388-3393
[55] Berumen J, Ordonez RM, Lazcano E, et al. Asian-American Variants of Human Papillomavirus 16 and Risk for Cervical Cancer: a Case-Control Study [J]. J. Natl. Cancer Inst. 2001,93:1325-1330
[56] Swan DC, Tucker RA, Tortolero-Luna G. et al. Human papillomavirus (HPV) DNA copy number is dependent on grade of cervical disease and HPV type [J]. J. Clin. Microbiol, 1999,37: 1030-1034
[57] Matsumoto K, Yoshikawa H, Nakagawa S, et al. Enhanced oncogenicity of human papillomavirus type 16 (HPV16) variants in Japanese population [J]. Cancer Letters, 2000,156:159-165
[58] Londesborough P, Ho L, Terry G, et al. Human papillomavirus genotype as a predictor of persistence and development of high-grade lesions in women with minor cervical abnormalities [J]. Int J Cancer 1996;69:364-8
[59] Zehbe I, Wilander E, Delius H, et al. Human papillomavirus 16 E6 variants are more prevalent in invasive cervical carcinoma than the prototype [J]. Cancer Res 1998;58:829 -33
[60] Zehbe I, Voglino G, Wilander E, et al. p53 codon 72 polymorphism and various human papillomavirus 16 E6 genotypes are risk factors for cervical cancer development [J]. Cancer Res 2001;61:608-11
[61] Zehbe I, Voglino G, Delius H, et al. Risk of cervical cancer and geographical variations of human papillomavirus 16 E6 polymorphisms [J]. Lancet 1998;352:1441-2
[62] Zehbe I, Tachezy R, Mytilineos J, Human papillomavirus 16 E6 polymorphisms in cervical lesions from different European populations and their correlation with human leukocyte antigen class II haplotypes [J]. Int. J. Cancer, 2001,94:711-716
[63] Matsumoto K, Yasugi, Nakagawa S, Human papillomavirus 16 E6 variants and HLA class II alleles among Japanese women with cervical cancer [J]. Int. J. Cancer, 2003,106:919-922
[64] Debbie Saslow, PhD, Carolyn D. Runowicz, MD, Diane Solomon, MD. et al. American Cancer Society Guideline for the Early Detection of Cervical Neoplasia and Cancer [J]. CA Cancer J Clin, 2002,52:342-362
[65] Kristine M. Zanotti, MD and Jerome Belinson, MD. Update on the diagnosis and treatment of human papillomavirus infection. [J]. Cleveland Clinic Journal of Medicine,2002, 69(12):948-961
[6
[66] Donna Hubbard McCree Ph.D., M.P.H., R.Ph., Jami S. Leichliter Ph.D. et al. National survey by specialty of U.S. physicians' HPV screening practices. [J] Preventive Medicine, 2003,36(2): 159-163
[67] Samutl Ratnam, Eduardo L. Franco, and Alex Ferenczy. Human papillomavirus Testing for Primary Screening of Cervical Cancer Precursors. [J] Cancer Epidemiology, 2000,9(9):945-951
[68] Romanczuk H, Vill L, Schlegel R. et al. The viral transcriptional regulatory region upstream of the E6 and E7 gene is a major determinant of the differential immortalization activities of human papillomavirus types 16 and 18. J Virol, 1991,65:2739-2743
[69] 马正海,钱东,马纪,等.新疆维吾尔族妇女宫颈癌组织中乳头瘤病毒16型E6基因的克隆和序列分析.生物化学与生物物理进展,2001,28(3):400-404
[70] 徐来祥,张知彬,宋铭晶,等.福尔马林保存的动物标本基因组DNA的提取方法.动物学报,2002,48(2):264-269
[71] Bosch FX, Manos MM, Mu(?)oz N, et al. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) study group. Journal of the National Cancer Institute, 1995,87(11):796-802
[72] Trofatter, K. F. Diagnosis of human papillomavirus genital tract infection. Am. J. Med., 1997,102:21-27
[73] Gibson EM, Heid CA, Williams PM. A novel method for real-time quantitative RT-PCR [J]. GenomeRes, 1996,6(8):995-1001
[74] Heid CA, Stevens J, Livak KJ, et al. Real time quantitative PCR [J]. Genome Res, 1996,6(8):986-994
[75] DEsjardin LE, chen Y, SD Perkins MD, et al. Comparison of the ABI 7700 system(TaqMan) andcompititive PCR for quantification of IS 6110 DNA in sputum during treatment of tuberculosis [J]Clin Microbil, 1998,36(7):1964-1968
[76] Agnetha Josefsson, Ken Livak and Ulf gyliensten. Detection and Quantitation of human papillomavirus by using the fluorescent 5' exonuclease assay. [J]. J of Clinical Microbiology , 1999,3:490-496
[77] Jin, X. W., J. Cash, and A. W. Kennedy. Human papillomavirus typing and the reduction of cervical cancer risk. Cleveland Clin. J. Med. 1999,66: 533-539
[78] Benny Almog, M.D., Ronni Gamzu, M.D., Michael J. Kuperminc, M.D. et al. Human papiloma Virus Testing in patient follow-up post cone biopsy due to high-grade cervical intraepithelial neoplasia. [J]Gynecologic Oncology, 2003,88:345-350
[79] Nathalie Ylitalo, Agnetha Josefeen, Mads Melbye et al. A Prospective Study Showing Long-term infection with Human papillomavirus 16 before the Development of Cervical Carcinoma in situ. [J]Cancer Research, 2000,60(11):6027-6032
[80] Rozendaal L, Walboorners JMM, Vander Linden JC, et al. PCR-based high risk HPV test in cervical cancer screening gives objective risk assessment of women with cytomorpho-logically normal cervical smears. Int J cancer, 1999,68:766-769
[81] Nathalie Ylitalo, Agnetha Josefeen, Mads Melbye et al. A Prospective Study Showing Long-term infection with Human papillomavirus 16 before the Development of Cervical Carcinoma in situ[J]. Cancer Research, 2000,60(11):6027-6032
[82] zur Elausen, H. Papiilomaviruses in human cancers. Proc. Assoc. Am. Physicians. 1999,111:581-587
[83] Jin, X. W., J. Cash, and A. W. Kennedy. Human papillomavirus typing and the reduction of cervical cancer risk. Cleveland Clin. J. Med. 1999,66:533-539
[84] Walboomers, J.M.M., M.V.Jacobs, M.M.Manos, et al. human papillomavirus is a necessary cause of invasive cervical cancer worldwide, j. pathol. 1999,189:12-19
[85] Andersson, S., E. Rylander, B.Larsson, A.Strand, et al. The role of human papillomavirus in cervical adenocarcnoma carcinogenesis. Eur.J.Cancer, 2001,37:246-250
[86] Calore, E.E., S.M.M.Pereira,and M.J.Cavaliere. Progression of cervical lesions in HIV-seropositive woman:a cytological study. Diagn. Cytopathol. 2001,24:117-119
[87] Heid CA, Stevens J, Livak KJ, et al. Real time quantitative PCR [J]. Genome Res, 1996,6(8):986-994
[88] DEsjardin LE, chen Y,SD Perkins MD, et al. Comparison of the ABI 7700 system(TaqMan) andcompititive PCR for quantification of IS 6110 DNA in sputum during treatment of tuberculosis [J]Clin Microbil, 1998,36(7): 1964-1968
[89] Harro, C. D., Y.-Y. S. Pang, R B. S. Roden, et al. Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vac-cine. J. Natl. Cancer Inst. 2001,93: 284-292
[90] Jin, X. W., J. Cash, and A. W. Kennedy. Human papillomavirus typing and the reduction of cervical cancer risk. Cleveland Clin. J. Med. 1999,66: 533-539
[91] Franco, E. L. Cancer causes revisited:human papillomavirus and cervical neoplasia. J. Natl. Cancer Inst. 1995,87:779-780
[92] Beaudenon, S.,D.Kremsdorf, O.Croillant,S.Jabonska, S.WainHobson, and G.Orth. A novel type of human papillomavirus associated with genital neoplasias. Nature, 1986,321:246-249
[93] Beaudenon, S,D.Kremsdorf, S.Obalek,S.Jablonska, G.PehauAmaudet, O.Croillant. Plurality of genital human papillomaviruses: characterization of two new types with distinct bilolgical prpoerties. Virlolgy, 1987,161: 373-384
[94] Bosch, R, M.Manos, N.Munoz, et al. Prevalence of human papillomvirus in cervical: a wordwide perspective. J. Natl. Cancer Inst. 1995, 87:796-802
[95] Fuchs, P. G., F. Girardi, and H. Pfister. Human papillomavirus DNA in normal, metaplastic, preneoplastic and neoplastic epithelia of the cervix uteri. Int. J. Cancer, 1988,41:41-45
[96] Gissmann, L., L. Wolnik, H. Ikenberg, et al. Human papillomavirus types 6 and 11 DNA se-quences in genital and laryngeal papillomas and in some cervical cancers. Proc. Natl. Acad. Sci. USA 1983,80: 560-563
[97] Lonquet, M., S. Beaudenon, and G. Orth. Two novel genital papil-Iomavirus (HPV) types: HPV68 and HPV70, related to the potentially oncogenic HPV39. J. Clin. Microbiol, 1996,34:738-744
[98] Lorincz, A. T., W. D. Lancaster, and G. F. Temple. Cloning and characterization of the DNA of a new human papillomavirus from a woman with dysplasia of the uterine cervix. J. Virol, 1986,58:225-229
[99] Lorincz, A. T, A. P. Quinn, W. D. Lancaster, and G. F. Temple. A new type of papillomavirus associated with cancer of the uterine cervix. Virology 1987,159:.187-190
[100]Lorincz, A. T, G. F. Temple, R J. Kurman, A. B. Jenson, and W. D. Lancaster. Oncogenic association of specific human papillomavirus types with cervical neoplasia. JNCI, 1987,79:671-677
[101]Lorincz, A. T., A. P. Quinn, M. D. Goldsborough, P. McAllister, and G. F.Temple. Human papillomavirus type 56: a new virus detected in cervical cancers. J. Gen. Virol. 1989,70:3099-3104
[102]Lorincz, A. T, A, P. Quinn, M. D. Goldsborough, B. J. Schmidt, and G. F. Temple. Cloning and partial DNA sequencing of two new human papillomavirus types associated with condylomas and! owgrade cervical neoplasia. J. Virol. 1989,63:2829-2834
[103]Lorincz, A. T, and IL Reid. Association of human papillomavirus with gynecological cancer. Curr. Opin. Oncol. 1989,1:123-132
[104]Lorincz, A. T, R. Reid, A. B. Jenson, M. D. Greenberg, W. Lancaster, and R. J. Kurman. Human papillomavirus infection of the cervix: relative risk associations of 15 common anogenital types. Obstet. Gynecol. 1992,79:328-337
[105]Manos, M. M., W. K. Kinney, L. B. Hurley, M. E. Sherman, J. Shieh-Ngai, R. J. Sherman, J. E. Ramsey, B. J. Fetterman, J. S. Hartinger, K. M. Mclntosh, G. F. Pawlik, and R. A. Htiatt. Identifying women with cervical neoplasia: Using human papillomavirus DNA testing for equivocal Papanicolaou results. JAMA 1999,281:1605-1610
[106]Munoz, N, F. X. Bosch, K. V. Shah, and A. Meheus. The epide-miology of cervical cancer and human papillomavirus. Scientific Publication 119. International Agency for Research on Cancer, Lyon, France, 1992
[107]Naghashfar, Z. S., N. B. Rosenshein, A. T. Lorincz, J. Buscema, and K. V. Shah. Characterization of human papillomavirus type 45, a new type 18-related virus of the genital tract. J. Gen. Virol. 1987,68: 3073-3079
[108]Nuovo, G. J., C, P. Crum, E. M. de Villiers, R. U. Levine, and S. J. Silverstein. Isolation of a novel human papillomavirus (type 51) from a cervical condyloma. J. Virol. 1988,62:1452-1455
[109]Reid, R, M. Greenberg, A. B. Jenson, M. Husain, J. Willett, Y. Daoud, G.Temple, C. R Stanhope, A. L Sherman, G. D. Phibbs, and A. T. Lorincz. Sexually transmitted papillomavirus infections. 1. The anatomic dis-tribution and pathogenic grade of neoplastic lesions associated with differ-ent viral types. Am. J. Obstet. Gynecol. 1987,156:212-222
[110]Rho, J. A. Roy-Burman, H. Kim, E. M. de Villiers, T. Matsukura, and J. Choe. Nucleotide sequence and phyiogenetic classification of hu-man papillomavirus type 59. Virology 1994,203:158- 161
[111]Shimoda, K., A. T. Losrincz, F. Temple, and W. D. Lancaster. Human papillomavirus type 52: a new virus associated with cervical neoplasia. J. Gen. Virol. 1988,69:2925-2928
[112]Swan, D. C, R. A. Tucker, G. Tortolero-Luna, et al. Human papilloma (HPV) DNA copy number is dependent on grade of cervical disease and HPV type. J. Clin. Microbiol. 1999,37:1030-1034
[113]Giannoudis, A., and C. S. Herrington. Human papillomavirus variants and squamous neoplasia of the cervix. J. Pathol. 2001,192: 395-302
[114]Quint, W. G. V, G. Scholte, L. J. Van Doom, et al. Comparative analysis of human papillomavirus infections in cervical scrapes and biopsy specimens by general SPF10 PCR and HPV genotyping. J. Pathol. 2001,194:51-57
[115]Schiffman, M., R. Herrero, A. Hildesheim, et al. HPV DNA testing in cervical cancer screening. Results from women in a high-risk province of Costa Rica. 2000,JAMA 283:87-93
[116]Nobbenhuis, M. A., C. J. Meijer, A. J. van den Brule, et al. Addition of high-risk HPV testing improves the current guidelines onfollow-up after treatment for cervical intraepithelial neoplasia. Br.j. cancer8, 2001,4:796-801
[117]Bosch FX, Manos MM, Munoz N, et al. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) study group. Journal of the National Cancer Institute, 1995,87(11):796-802
[118]Bosch, F., M.Manos, N.Munoz, et al. Prevalence of human papillomvirus in cervical:a wordwide perspective. J. Natl. Cancer Inst. 1995,87:796-802
[119]Swan, D. C, R. A. Tucker, G. Tortolero-Luna, M. F. Mitchell, L. Wideroff, E. R. Unger, R. A. Nisenbaum, W. C. Reeves, and J. P. Icenogle. 1999
[120]Zerbini, M., S. Venturoli, M. Cricca, G. Gallinella, P. De Simone, S. Costa, D. Santini, and M. Musiani. Distribution and viral load of type specific HPVs in different cervical lesions as detected by PCR-ELISA. J. Clin. Pathol. 2001,54:377-380
[121]Holowaty, P., A. B. Miller, T. Rohan, et al. Natural dysplasia of the uterine cervix. J. Natl. Cancer Inst. 1999,91:252-258
[122]Wright, T. C, and IL T. Kurman. A critical review of the morphologic classification system of preinvasive lesions of the cervix: the scientific basis for shifting the paradigm. Papillomavirus Rep. 1994,S:175-182
[123]Spitzer, M. Cervical screening adjuncts: recent advances. Am. J. Obstet. Gynecol. 1998,179:544-556
[124]enny Almog, M.D., Ronni Gamzu, M.D.,Michael J. Kuperminc,M.D. et al. Human papiloma Virus Testing in patient follow-up post cone biopsy due to high-grade cervical intraepithelial neoplasia. [J]Gynecologic Oncology, 2003,88:345-350
[125]Nathalie Ylitalo, Agnetha Josefeen, Mads Melbye et al. A Prospective Study Showing Long-term infection with Human papillomavirus 16 before the Development of Cervical Carcinoma in situ[J]. Cancer Research, 2000, 60(11):6027-6032
[126]Rozendaal L, Walboorners JMM, Vander Linden JC, et al. PCR-based high risk HPV test in cervical cancer screening gives objective risk assessment of women with cytomorpho-logically normal cervical smears. Int J cancer, 1999,68:766-769
[127]Nathalie Ylitalo, Agnetha Josefeen, Mads Melbye et al. A Prospective Study Showing Long-term infection with Human papillomavirus 16 before the Development of Cervical Carcinoma in situ. [J]Cancer Research, 2000,60(11):6027-6032
[128]Dalal S, Gao Q, Androphy EJ, et al. Mutational analysis of human papillomavirus type 16 E6 demonstrates that p53 degradation is necessary for immortalization of mammary epithelial cells[J]. Virology, 1996,70(2): 2683-2688
[129]Lebuanec H, Anna RD, Achgar AL, et al. HPV16 E7 but not E6 oncogenic protein triggers both cellular immunosuppression and angiogenic processes [J]. Biomedicine & Pharmacother, 1999,53(4): 424-431
[130]Herrington CS. Human papillomaviruses and cervical neoplasia. II. Interation of HPV with other factors[J]. Clin Pathol 1995,48(1): 1-6
[131]Lebuanec H, Anna RD, Achgar AL, et al. HPV16 E7 but not E6 oncogenic protein triggers both cellular immunosuppression and angiogenic processes [J]. Biomed & Pharmacother. 1999,53(4):424-431
[132]Foster SA, Galloway DA.Human papillomavirus type 16 E7 alleviates aproliferation block in early passage human mammary epithelial cells[J]. Oncogene. 1996,12 (8): 1773-1779
[133]Androphy EJ. Molecular biology of human papillomavirus infection and oncogenesis[J]. Invest Dermatol. 1994,103 (2):248-256
[134]Dalal S, Gao Q, Androphy EJ, et al. Mutational analysis of human papillomavirus type 16 E6 demonstrates that p53 degradation is necessary for immortalization of mammary epithelial cells[J]. Virology, 1996,70(2): 2683-2688
[135]Lebuanec H, Anna RD, Achgar AL, et al. HPV 16 E7 but not E6 oncogenic protein triggers both cellular immunosuppression and angiogenic processes [J]. Biomedicine & Pharmacother, 1999,53(4): 424-431
[136]LowyDR, KimbauerR, SchillerJT. Genitalhumanpa-pillomavirus in fection [J]. ProNatlAcadSciUSA, 1994,91:2436-2440
[137]HausenH, VilliersEM. Humanpapillomavirus[J]. AnnuRevMicrobiol, 1994,4 8:427
[138]SongSY, PitotHC, LambertPF. The human papillomavirus type16E6 gene alone is sufficient to induce carcinomas in transgenic animals [J]. JVirol, 1999,73(7):5887-5893
[139]SeedorfK, KraemmerG, DuerstM, et al. Human papilloma virus type16DNA sequence [J]. JVirol, 1985,145:181-191
[140]Swan DC, Tucker RA, Tortolero-Luna G. et al. Human papillomavirus (HPV) DNA copy number is dependent on grade of cervical disease and HPV type [J]. J. Clin. Microbiol, 1999,37: 1030-1034
[141]Foster SA, Galloway DA. Human papillomavirus type 16 E7 alleviates aproliferation block in early passage human mammary epithelial cells[J]. Oncogene. 1996,12 (8):1773-1779
[142]Storhoff J J, Elghanian R, Mucic R C, et al. "One-Pot Colorimetric Differentiation of Polynucleotides with Single Base Imperfections Using Gold Nanoparticle Probes," J. Am. Chem. Soc, 1998,120, 1959-1964
[143]Taton T A, Mirkin C A, Letsinger R L. "Scanometric DNA Array Detection with Nanoparticle Probes" Science, 2000,289,1757-1760
[144]Park S J, Taton T A, Mirkin C A. "Array-Based Electrical Detection of DNA Using Nanoparticle Probes," Science, 2002,295(5559), 1503-1506
[145]Cao Y C, Jin R, Mirkin CA. Nanoparticles with Raman spectroscopic fingerprints for DNA and RNA detection. Science. 2002,297(5586): 1536-1540
[146]Dyson N, Howley P M, Munger K, et al.The human papilloma virus: 16 E7 oncoprotein is able to the retinoblastoma gene product. Science, 1989,243: 934-937
[147]Hausen H. Papillomavirus infections: a major cause of human cancers. Biochim. Biophys. Acta 1996,1228:F55-F78
[148]Lorincz A T, Reid R, Bennett A, et al. Human papillomavirus infection of the cervix: relative riskassociations of 15 common anogenital types. Obstet. Gynecol. 1992,79:328-337
[1
[149] Scheffner M, Huibregtse J M, Vierstra R D, et al. The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53. Cell, 1993,75:495-505
[150] Trofatter K F. Diagnosis of human papillomavirus genital tract infection. Am. J. Med. 1997,102 (5A): 21-27
[151] Li T F(李庭芳),G μ Lnar K(古丽娜.库尔班),Wang T(王涛),et al. A study on the prevention and therapy of carcinoma of the cervix in xapt μ L township jashi county, xinjiang. Acta Academiae Medicinae Xinjiang(新疆医学院学报),1996,19(3):199～203
[152] Lalai S(拉莱.苏祖克),G μ Lnar K(古丽娜.库尔班),Amy E,et al. Immunostaining of the p53 gene and detection of human papillomavirus in cervical carcinoma of uygur women. Acta Academiae Medicinae Xinjiang(新疆医学院学报),1997,20(2):77-81
[153] Ma ZH H(马正海),Qian D(钱东),Ma J(马纪),et al.Cloning and sequenceing of HPV16E6 gene from cervical carcinoma biopsies in Xinjiang. Prog. Biochem. Biophys(生物化学与生物物理进展).2001,28(3):400-404
[154] Moller R, Csaki A, Kohler JM, et al. DNA probes on chip surfaces studied by scanning force microscopy using specific binding of colloidal gold. Nucleic Acids Research. 2000,28(20):e91
[155] Gravitt P E, Peyton C L,Apple R J, et al. Genotyping of 27 Human Papillomavirus Types by Using L1 Consensus PCR Products by a Single-Hybridization, Reverse Line Blot Detection Method. J Clin Microbiol, 1998,36(10):3020-3027
[156] zur hausen, H. Papiliomavirus infections a major cause of human cancers. Biochim. Biophys. Acta. 1996,1288:55-78
[157] Conrad-Stoppler, M. C., K. Ching, H. Stoppler, et al. Natural variants of the human papillomavirus type 16 E6 protein differ in their abilities to alter keratinocyte differentiation and to induce p53 degradation. J. Virol. 1996,70:6987-6993
[158]Veress, G, K, Szarka, X.-P. Dong, L. Gergely, et al. Func-tional significance of sequence variation in the E2 sene and the long control region of human papillomavirus type 16. J. Gen. Virol. 1999,80: 1053-1043